Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.

Lung Cancer Manag · 2026 · PMC12885437 · PMID 41634566

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Base-case analysis Applying the 12-month cumulative incidence of BM progression in patients receiving lorlatinib and crizotinib as first-line (1 L) treatment observed in the CROWN trial, lorlatinib therapy showed a trend of reducing management costs compared with crizotinib.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.